|
Volumn 16, Issue 9, 2002, Pages 1668-1672
|
Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL
a b a b a b b c d e |
Author keywords
ALL; Allogeneic stem cell transplantation; MRD
|
Indexed keywords
BUSULFAN;
CYCLOPHOSPHAMIDE;
CYCLOSPORIN A;
ETOPOSIDE;
LYMPHOCYTE ANTIBODY;
LYMPHOCYTE ANTIGEN RECEPTOR;
METHOTREXATE;
MOLECULAR MARKER;
OKT 3;
THIOTEPA;
ACUTE LYMPHOCYTIC LEUKEMIA;
ADOLESCENT;
ALLOGENIC BONE MARROW TRANSPLANTATION;
ARTICLE;
CANCER SURVIVAL;
CHILD;
CHILDHOOD LEUKEMIA;
CONTROLLED STUDY;
CORRELATION ANALYSIS;
DISEASE MARKER;
DONOR;
ELECTROPHORESIS;
FEMALE;
GENE AMPLIFICATION;
GENE REARRANGEMENT;
GRAFT VERSUS HOST REACTION;
GRAFT VERSUS LEUKEMIA EFFECT;
HIGH RISK PATIENT;
HUMAN;
HUMAN CELL;
HUMAN TISSUE;
IMMUNOPHENOTYPING;
IMMUNOSUPPRESSIVE TREATMENT;
LEUKEMIA CELL;
LEUKEMIA REMISSION;
MAJOR CLINICAL STUDY;
MALE;
MINIMAL RESIDUAL DISEASE;
MOLECULAR CLONING;
MULTIVARIATE ANALYSIS;
OLIGONUCLEOTIDE PROBE;
POLYMERASE CHAIN REACTION;
PRIORITY JOURNAL;
RECEPTOR GENE;
RETROSPECTIVE STUDY;
SENSITIVITY ANALYSIS;
SEX DIFFERENCE;
STEM CELL TRANSPLANTATION;
TREATMENT OUTCOME;
|
EID: 0036736498
PISSN: 08876924
EISSN: None
Source Type: Journal
DOI: 10.1038/sj.leu.2402552 Document Type: Article |
Times cited : (154)
|
References (17)
|